Comparing two drugs for lupus treatment
Part of Immune system & allergy, Skin clinical trials.
This study compares two medications, Telitacicept and Belimumab, to see which works better for people with active lupus that hasn't improved with standard treatments. The goal is to find a more effective option for managing symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 65
- Diagnosed with lupus based on standard medical criteria
- Moderate to severe lupus activity with a score of 8 or more on a disease activity scale
- Not well-controlled with current lupus medications like steroids or immunosuppressants
- Willing to take one of the two study drugs
- No active serious infections like HIV, hepatitis, or central nervous system lupus
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medicine called Telitacicept to see if it can prevent lupus flares in people whose disease is currently mild or stable. It may be a good option if you want to keep your lupus under control and avoid sudden worsening.
This trial tests a new biologic drug called telitacicept for people with systemic lupus erythematosus (SLE). It aims to see how safe and effective the drug is and may offer a new treatment option for lupus.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
This trial tests if a new drug called telitacicept works better than a standard lupus medicine (cyclophosphamide) to improve lupus-related lung scarring (interstitial lung disease). It might be an option if your breathing tests are still good enough.
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
This trial tests a new treatment called CM355 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. It aims to see if the drug can help control disease activity in patients whose lupus is not well managed by current therapies.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.